The last paragraph of this article has been corrected to note that the $150 million in funding is in support of the Strategic Research Initiative.

NEW YORK (GenomeWeb) – Researchers at Indiana University have announced the launch of a new study in which they will use targeted sequencing provided by testing firm Paradigm to try to direct personalized treatment strategies for women with triple-negative breast cancer (TNBC) in the hopes of extending their lives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.